FY2028 EPS Estimate for Ionis Pharmaceuticals Cut by Analyst

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Investment analysts at William Blair decreased their FY2028 earnings estimates for Ionis Pharmaceuticals in a research note issued to investors on Friday, December 20th. William Blair analyst M. Minter now forecasts that the company will earn $2.07 per share for the year, down from their previous forecast of $2.26. William Blair has a “Outperform” rating on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.37) per share.

A number of other research firms have also issued reports on IONS. Guggenheim lowered their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Piper Sandler decreased their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. StockNews.com cut shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $70.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, September 26th. Finally, Wells Fargo & Company lowered their price objective on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $60.65.

Ionis Pharmaceuticals Stock Performance

Shares of Ionis Pharmaceuticals stock opened at $36.08 on Monday. Ionis Pharmaceuticals has a 12 month low of $33.33 and a 12 month high of $54.44. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The stock has a market capitalization of $5.70 billion, a price-to-earnings ratio of -14.79 and a beta of 0.35. The firm’s fifty day simple moving average is $37.33 and its 200-day simple moving average is $42.26.

Insiders Place Their Bets

In related news, CEO Brett P. Monia sold 6,630 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $38.05, for a total value of $252,271.50. Following the sale, the chief executive officer now directly owns 167,393 shares in the company, valued at $6,369,303.65. The trade was a 3.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Eric Swayze sold 1,194 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48. Following the sale, the executive vice president now owns 33,713 shares of the company’s stock, valued at $1,278,396.96. The trade was a 3.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,877 shares of company stock worth $299,578. 2.71% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Great Point Partners LLC acquired a new stake in shares of Ionis Pharmaceuticals during the second quarter worth approximately $15,728,000. International Assets Investment Management LLC boosted its holdings in Ionis Pharmaceuticals by 3,287.0% in the third quarter. International Assets Investment Management LLC now owns 328,772 shares of the company’s stock worth $13,171,000 after purchasing an additional 319,065 shares in the last quarter. Logos Global Management LP bought a new position in Ionis Pharmaceuticals during the second quarter valued at about $14,298,000. Baker BROS. Advisors LP acquired a new stake in shares of Ionis Pharmaceuticals in the third quarter worth about $8,952,000. Finally, Geode Capital Management LLC raised its stake in shares of Ionis Pharmaceuticals by 7.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock valued at $106,922,000 after acquiring an additional 183,814 shares in the last quarter. 93.86% of the stock is owned by hedge funds and other institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.